A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

@article{Armstrong2007ACP,
  title={A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.},
  author={Andrew James Armstrong and Elizabeth Garrett-Mayer and Yi-Chun Yang and Ronald de Wit and Ian F. Tannock and Mario A. Eisenberger},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 21},
  pages={
          6396-403
        }
}
PURPOSE To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC). EXPERIMENTAL DESIGN TAX327 was a clinical trial that randomized 1,006 men with metastatic HRPC to receive every three week or weekly docetaxel or mitoxantrone, each with prednisone. We developed a multivariate Cox model and nomogram to predict survival at 1, 2, and 5 years. RESULTS Ten independent prognostic factors other… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 148 CITATIONS

Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review

  • World Journal of Urology
  • 2018
VIEW 10 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

The changing landscape in the treatment of metastatic castration-resistant prostate cancer.

  • Therapeutic advances in medical oncology
  • 2013
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.

  • Critical reviews in oncology/hematology
  • 2016
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 9 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Natural history of rising serum prostate - specific antigen in men with castrate nonmetastatic prostate cancer

P Zhou, ChenMH, D McLeod, PR Carroll, D’Amico AV MoulJW
  • J Clin Oncol
  • 2005

Prognostic significance of plasma chromogranin A levels in patients with hormone - refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

EJ Small, MeyerM, ME Marshall
  • Urology
  • 2005

The prognostic significance of plasma interleukin - 6 levels in patients with metastatic hormone - refractory prostate cancer : results from cancer and leukemia group B 9480

RA Ghossein, J Rosai, HI Scher
  • Clin Cancer Res
  • 2005

Similar Papers

Loading similar papers…